You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm is taking its in-home monitoring systems for COPD and cystic fibrosis, and its professional-use sepsis confirmation system through clinical trials.
The partnership will enable the design, development, and manufacture of a test to rapidly detect dengue, Chikungunya, and Zika viruses.
The assay provides a presumptive diagnosis of dengue virus from patients' serum samples within the first seven days of clinical symptoms.
They have begun field testing near-infrared spectroscopy as an alternative to PCR and ELISA for routine pathogen screening in mosquitoes.
The tests are based on Chembio's Dual Path Platform chromatographic immunoassay technology, which can detect antibodies within 15 minutes using fingerstick samples.
The team paired the SHERLOCK platform developed in Feng Zhang's lab with a protocol that detects viruses directly from bodily fluids in less than two hours.
The latest version of the nucleic acid detection platform uses three CRISPR enzymes, making it more sensitive and capable of smaller quantitative measurements.
The device is an electrochemical lateral flow immunosensor test that will initially be used to detect dengue hemorrhagic fever, and later, to assess stroke severity.
The test, which uses an immunochromatography format similar to a home pregnancy test, could enable quick, inexpensive testing for Zika and dengue infections.
The University of Illinois team developed the technology with an eye at low-resource settings, including developing nations and rural communities.